Gennex Laboratories [GENNEX] vs Suven Life Sciences [SUVEN] Detailed Stock Comparison
Gennex Laboratories
BSE
Loading...
Suven Life Sciences
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Gennex Laboratories wins in 10 metrics, Suven Life Sciences wins in 8 metrics, with 0 ties. Gennex Laboratories appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Gennex Laboratories | Suven Life Sciences | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 16.41 | -28.31 | Suven Life Sciences |
| Price-to-Book Ratio | 1.18 | 41.36 | Gennex Laboratories |
| Debt-to-Equity Ratio | 13.93 | 0.00 | Suven Life Sciences |
| PEG Ratio | 2.80 | -0.34 | Suven Life Sciences |
| EV/EBITDA | 15.81 | -24.12 | Suven Life Sciences |
| Profit Margin (TTM) | 11.46% | 84.44% | Suven Life Sciences |
| Operating Margin (TTM) | 13.37% | -2,791.92% | Gennex Laboratories |
| EBITDA Margin (TTM) | 13.37% | N/A | N/A |
| Return on Equity | 9.31% | -146.15% | Gennex Laboratories |
| Return on Assets (TTM) | 7.08% | -118.91% | Gennex Laboratories |
| Free Cash Flow (TTM) | $-197.44M | $-1.91B | Gennex Laboratories |
| 1-Year Return | -41.07% | 46.77% | Suven Life Sciences |
| Price-to-Sales Ratio (TTM) | 2.16 | 632.35 | Gennex Laboratories |
| Enterprise Value | $2.75B | $44.90B | Suven Life Sciences |
| EV/Revenue Ratio | 1.92 | 597.31 | Gennex Laboratories |
| Gross Profit Margin (TTM) | 35.05% | 100.00% | Suven Life Sciences |
| Revenue per Share (TTM) | $7 | $0 | Gennex Laboratories |
| Earnings per Share (Diluted) | $0.78 | $-8.45 | Gennex Laboratories |
| Beta (Stock Volatility) | 0.31 | 0.78 | Gennex Laboratories |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Gennex Laboratories vs Suven Life Sciences Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Gennex Laboratories | -0.55% | 8.38% | 11.50% | 2.32% | -9.28% | -25.32% |
| Suven Life Sciences | 0.37% | -0.20% | -3.13% | -15.86% | 58.76% | 63.09% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Gennex Laboratories | -41.07% | 96.92% | 228.21% | 181.32% | 759.06% | 975.63% |
| Suven Life Sciences | 46.77% | 186.97% | 307.88% | -25.87% | 594.28% | 3,728.07% |
News Based Sentiment: Gennex Laboratories vs Suven Life Sciences
Gennex Laboratories
News based Sentiment: MIXED
Gennex Laboratories experienced a stock price reversal and reported positive Q1 FY2026 results, but continues to face significant long-term declines and saw a large insider sell transaction. These mixed signals create a complex investment picture, making October a noteworthy but not transformative month for the company.
Suven Life Sciences
News based Sentiment: POSITIVE
The month of October 2025 saw Suven Life Sciences benefit from both company-specific gains and a broader pharmaceutical rally, indicating a positive trend for the company. The Pfizer agreement acted as a catalyst for this positive movement, suggesting a favorable market environment.
Performance & Financial Health Analysis: Gennex Laboratories vs Suven Life Sciences
| Metric | GENNEX | SUVEN |
|---|---|---|
| Market Information | ||
| Market Cap | ₹3.11B | ₹47.99B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 642,874 | 184,111 |
| 90 Day Avg. Volume | 571,621 | 150,383 |
| Last Close | ₹12.73 | ₹209.40 |
| 52 Week Range | ₹10.84 - ₹19.00 | ₹102.50 - ₹299.99 |
| % from 52W High | -33.00% | -30.20% |
| All-Time High | ₹29.00 (Sep 16, 2024) | ₹338.50 (Apr 13, 2015) |
| % from All-Time High | -56.10% | -38.14% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.21% | 0.86% |
| Quarterly Earnings Growth | 0.08% | 0.86% |
| Financial Health | ||
| Profit Margin (TTM) | 0.11% | 0.84% |
| Operating Margin (TTM) | 0.13% | -27.92% |
| Return on Equity (TTM) | 0.09% | -1.46% |
| Debt to Equity (MRQ) | 13.93 | 0.00 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹10.85 | ₹5.04 |
| Cash per Share (MRQ) | ₹2.40 | ₹2.75 |
| Operating Cash Flow (TTM) | ₹-75,467,000 | ₹-1,590,282,000 |
| Levered Free Cash Flow (TTM) | ₹181.23M | ₹-1,607,450,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | ₹0.00 | ₹0.00 |
Valuation & Enterprise Metrics Analysis: Gennex Laboratories vs Suven Life Sciences
| Metric | GENNEX | SUVEN |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 16.41 | -28.31 |
| Forward P/E | N/A | 10.78 |
| PEG Ratio | 2.80 | -0.34 |
| Price to Sales (TTM) | 2.16 | 632.35 |
| Price to Book (MRQ) | 1.18 | 41.36 |
| Market Capitalization | ||
| Market Capitalization | ₹3.11B | ₹47.99B |
| Enterprise Value | ₹2.75B | ₹44.90B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.92 | 597.31 |
| Enterprise to EBITDA | 15.81 | -24.12 |
| Risk & Other Metrics | ||
| Beta | 0.31 | 0.78 |
| Book Value per Share (MRQ) | ₹10.85 | ₹5.04 |
Financial Statements Comparison: Gennex Laboratories vs Suven Life Sciences
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | GENNEX | SUVEN |
|---|---|---|
| Revenue/Sales | ₹341.78M | ₹18.67M |
| Cost of Goods Sold | ₹221.97M | ₹0 |
| Gross Profit | ₹119.81M | ₹18.67M |
| Research & Development | N/A | ₹414.88M |
| Operating Income (EBIT) | ₹45.68M | ₹-521.17M |
| EBITDA | ₹73.49M | ₹-501.49M |
| Pre-Tax Income | ₹58.66M | ₹-515.17M |
| Income Tax | ₹8.50M | ₹0 |
| Net Income (Profit) | ₹50.16M | ₹-515.17M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | GENNEX | SUVEN |
|---|---|---|
| Cash & Equivalents | ₹545.89M | ₹150.26M |
| Total Current Assets | ₹1.81B | ₹754.72M |
| Total Current Liabilities | ₹445.55M | ₹234.86M |
| Long-Term Debt | ₹168.93M | N/A |
| Total Shareholders Equity | ₹1.95B | ₹1.10B |
| Retained Earnings | ₹562.59M | ₹-6.01B |
| Property, Plant & Equipment | ₹88.69M | ₹756.69M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | GENNEX | SUVEN |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | GENNEX | SUVEN |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 642,874 | 184,111 |
| Average Daily Volume (90 Day) | 571,621 | 150,383 |
| Shares Outstanding | 227.45M | 218.07M |
| Float Shares | 132.11M | 67.61M |
| % Held by Insiders | 0.31% | 0.69% |
| % Held by Institutions | 0.00% | 0.02% |
Dividend Analysis & Yield Comparison: Gennex Laboratories vs Suven Life Sciences
| Metric | GENNEX | SUVEN |
|---|---|---|
| Last 12-Month Dividend | ₹0.00 | ₹0.00 |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | ₹0.00 | ₹0.00 |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | ₹0.00 | ₹0.00 |
| Ex-Dividend Date | N/A | N/A |